Applied BioMath (www.appliedbiomath.com), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), today announced a continuation of their collaboration with Celsius Therapeutics for the development of a systems pharmacology model of a monoclonal antibody for the treatment of inflammatory bowel disease (IBD).
In this continued collaboration, Applied BioMath will develop an in vitro and human systems pharmacology model to support human dose predictions.
"We chose to continue our work with Applied BioMath due to the scientific excellence and collaborative approach we experienced in our previous project," said Jeanne Magram, PhD, CSO at Celsius Therapeutics. "The model results will provide critical insight as we prepare for IND filing."
Applied BioMath offers software and services to help de-risk and accelerate drug R&D. Their solutions, which focus on quantitatively integrating knowledge about therapeutics with an understanding of its mechanism of action in the context of human disease mechanisms, are leveraged across the entire R&D spectrum from early research through to clinical trials. Their approach involves working with clients to develop the appropriate mathematical strategy for each unique project, with common strategies encompassing systems pharmacology, mechanistic modeling, bioinformatics, biosimulation, and clinical pharmacology.
"We are proud to continue working with Celsius Therapeutics to provide support for their program," said John Burke, PhD, Co-founder, President and CEO at Applied BioMath. "MID3 helps define better human dose predictions by providing a holistic approach of integrating available knowledge, preclinical data, and competitor or comparator data."
To learn more about Applied BioMath, visit www.appliedbiomath.com.
About Applied BioMath
Founded in 2013, Applied BioMath's mission is to revolutionize drug invention. Applied BioMath applies biosimulation, including quantitative systems pharmacology, PKPD, bioinformatics, machine learning, clinical pharmacology, and software solutions to provide quantitative and predictive guidance to biotechnology and pharmaceutical companies to help accelerate and de-risk therapeutic research and development. Their approach employs proprietary algorithms and software to support groups worldwide in decision-making from early research through all phases of clinical trials. The Applied BioMath team leverages their decades of expertise in biology, mathematical modeling and analysis, high-performance computing, and industry experience to help groups better understand their therapeutic, its best-in-class parameters, competitive advantages, patients, and the best path forward into and in the clinic to increase likelihood of clinical concept and proof of mechanism, and decrease late stage attrition rates. For more information about Applied BioMath and its services and software, visit www.appliedbiomath.com.
Applied BioMath and the Applied BioMath logo are registered trademarks of Applied BioMath, LLC.
Press contact:
Kristen Zannella
kristen.zannella@appliedbiomath.com